Clinical handbook of insomnia
Clinical handbook of insomnia
Hrayr P. Attarian, editor.
- Third edition.
- 1 recurso en línea
- Current clinical neurology .
Preface; Series Editor Introduction; Contents; List of Editor and Contributors; Part I: Chronic Insomnia Disorder; Chapter 1: Defining Insomnia; Introduction; Historical Perspectives; Definitions of Insomnia; Classifications; Classification Based on Duration and Severity; Duration of Illness; Severity of Illness; Commonalities and Problems with Current Definitions; Insomnia as a Subjective Complaint; Insomnia and Daytime Impairment; The Old Diagnostic Entity of Comorbid or Secondary Insomnia; Summary; References; Chapter 2: Epidemiology of Insomnia; Sociodemographic Determinants Gender Age; Ethnocultural Factors; Shift Work; Other Factors; Psychiatric Disorders; Morbidity and Mortality; Epidemiology of Hypnotic Use; Economic Impact of Insomnia; Conclusion; References; Chapter 3: Clinical Features, Diagnosis, and Differential Diagnosis; Introduction; Clinical Features; Clinical Subtype Features; Diagnostic Workup; Differential Diagnosis; Appendix 1; References; Chapter 4: Pathophysiology of Insomnia; Introduction; Historical Studies of Insomnia; Modeling Studies of Insomnia and Physiological Activation; The Effects of Poor Sleep Key Pharmacologic Issues Prescription and Non-prescription Agents Approved by FDA for Treatment of Insomnia; Benzodiazepine Receptor Agonists; Mechanism of Action; Pharmacokinetics; Efficacy; Safety; Residual Effects; Sedation; Driving Performance; Fall Risk; Amnesia; Complex Behaviors During Sleep; Mortality Risk; Tolerance, Dependence, Abuse Potential; Discontinuation Effects; Melatonin Receptor Agonists; Ramelteon; Melatonin; Orexin Antagonists; Histamine (H1) Antagonists; Selective H1 Antagonist: Doxepin 3-6 mg; Nonselective H1 Antagonists: Diphenhydramine, Doxylamine Neurocognitive Perspective Assessment and Measurement; Self-Report Assessment; Objective Assessment; Cognitive-Behavioral Treatment; Therapeutic Regimen; First-Line Interventions; Stimulus Control Therapy; Sleep Restriction; Sleep Hygiene Education; Cognitive Therapy; Relaxation Training; Phototherapy; Complicating Factors; Treatment Compliance; Comorbidity of Mental and Medical Disorders; CBT and Sedative Hypnotics; The Efficacy of CBT; Abbreviated Versions of CBT-I; Technology and CBT; Summary; References; Chapter 7: Pharmacological Treatment of Insomnia; Introduction Poor Sleep in Insomnia Patients The Development of Insomnia; Medical Implications of These Physiological Arousal Data; Elevated Blood Pressure/Hypertension; Glycemic Control/Diabetes; Depression; Immune Function; Mortality; Discussion; References; Chapter 5: Prognosis and Complications; Prognosis and Complications; Psychiatric Disorders; Neurocognitive Function; Metabolic Disorders; Cardiovascular Disease; Burden of Illness; References; Chapter 6: Cognitive Behavioral Therapy for Insomnia; Theoretical Perspectives on Insomnia; Behavioral Perspective; Cognitive Perspective
3319414003 9783319414003
Insomnio
RC548 / 2017 EB
Preface; Series Editor Introduction; Contents; List of Editor and Contributors; Part I: Chronic Insomnia Disorder; Chapter 1: Defining Insomnia; Introduction; Historical Perspectives; Definitions of Insomnia; Classifications; Classification Based on Duration and Severity; Duration of Illness; Severity of Illness; Commonalities and Problems with Current Definitions; Insomnia as a Subjective Complaint; Insomnia and Daytime Impairment; The Old Diagnostic Entity of Comorbid or Secondary Insomnia; Summary; References; Chapter 2: Epidemiology of Insomnia; Sociodemographic Determinants Gender Age; Ethnocultural Factors; Shift Work; Other Factors; Psychiatric Disorders; Morbidity and Mortality; Epidemiology of Hypnotic Use; Economic Impact of Insomnia; Conclusion; References; Chapter 3: Clinical Features, Diagnosis, and Differential Diagnosis; Introduction; Clinical Features; Clinical Subtype Features; Diagnostic Workup; Differential Diagnosis; Appendix 1; References; Chapter 4: Pathophysiology of Insomnia; Introduction; Historical Studies of Insomnia; Modeling Studies of Insomnia and Physiological Activation; The Effects of Poor Sleep Key Pharmacologic Issues Prescription and Non-prescription Agents Approved by FDA for Treatment of Insomnia; Benzodiazepine Receptor Agonists; Mechanism of Action; Pharmacokinetics; Efficacy; Safety; Residual Effects; Sedation; Driving Performance; Fall Risk; Amnesia; Complex Behaviors During Sleep; Mortality Risk; Tolerance, Dependence, Abuse Potential; Discontinuation Effects; Melatonin Receptor Agonists; Ramelteon; Melatonin; Orexin Antagonists; Histamine (H1) Antagonists; Selective H1 Antagonist: Doxepin 3-6 mg; Nonselective H1 Antagonists: Diphenhydramine, Doxylamine Neurocognitive Perspective Assessment and Measurement; Self-Report Assessment; Objective Assessment; Cognitive-Behavioral Treatment; Therapeutic Regimen; First-Line Interventions; Stimulus Control Therapy; Sleep Restriction; Sleep Hygiene Education; Cognitive Therapy; Relaxation Training; Phototherapy; Complicating Factors; Treatment Compliance; Comorbidity of Mental and Medical Disorders; CBT and Sedative Hypnotics; The Efficacy of CBT; Abbreviated Versions of CBT-I; Technology and CBT; Summary; References; Chapter 7: Pharmacological Treatment of Insomnia; Introduction Poor Sleep in Insomnia Patients The Development of Insomnia; Medical Implications of These Physiological Arousal Data; Elevated Blood Pressure/Hypertension; Glycemic Control/Diabetes; Depression; Immune Function; Mortality; Discussion; References; Chapter 5: Prognosis and Complications; Prognosis and Complications; Psychiatric Disorders; Neurocognitive Function; Metabolic Disorders; Cardiovascular Disease; Burden of Illness; References; Chapter 6: Cognitive Behavioral Therapy for Insomnia; Theoretical Perspectives on Insomnia; Behavioral Perspective; Cognitive Perspective
3319414003 9783319414003
Insomnio
RC548 / 2017 EB